Skinabin 15 G

100110203500101

Skinabin 15 G

65.00৳ 

Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)

Description

Indications

Terbinafine tablet: This tablet is used to treat dermatophytes-caused onychomycosis of the toenail or fingernail (tinea unguium).

Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceus), Microsporum canis, and Epidermophyton floccosum cause fungal infections of the skin. Yeast infections of the skin, mostly caused by the Candida genus (e.g. C. albicans). Due to Pityrosporum orbiculare, pityriasis (tinea) versicolor develops (also known as Malassezia furfur).

Pharmacology

Terbinafine, an antifungal Allylamine, inhibits the formation of Ergosterol (an important component of fungi cell membranes) by inhibiting the Squalene Epoxidase enzyme. This causes fungal cell death mostly due to increased membrane permeability caused by high levels of Squalene buildup, rather than Ergosterol insufficiency. Terbinafine hydrochloride may be fungicidal depending on the medication concentration and the fungus species tested in vitro. The clinical value of in vitro data, on the other hand, remains unknown. Terbinafine has been proven to be effective in vitro and in clinical infections against the majority of strains of the following microorganisms: Trichophyton Menta Tricophyton Menta Tricophyton Menta.

Dosage & Administration

Terbinafine tablet:

  • For the treatment of fingernail onychomycosis: Terbinafine 250 mg (one tablet), once daily for 6 weeks.
  • For the treatment of toenail onychomycosis: Terbinafine 250 mg (one tablet), once daily for 12 weeks.
  • The optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for the outgrowth of healthy nails.

Terbinafine cream: Terbinafine cream can be applied once or twice daily. Cleanse and dry the affected areas thoroughly before the application of the terbinafine cream. Apply the cream to the affected skin and the surrounding area in a thin layer and rub it lightly. In the case of intertriginous infections (submammary, interdigital, intergluteal, inguinal) the application may be covered with a gauze strip, especially at night. The likely durations of treatment are as follows:

  • Tinea corporis, cruris: 1 to 2 weeks
  • Tinea pedis: 1 week
  • Cutaneous candidiasis: 2 weeks
  • Pityriasis Versicolor: 2 weeks

Relief of the clinical symptoms usually occurs within a few days. Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified.

Interaction

Terbinafine inhibits the CYP450 2D6 isozyme in vivo, according to research. Tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone), and monoamine oxidase inhibitors Type B are among the drugs processed mostly by the CYP450 2D6 isozyme. Co-administration of terbinafine should be done with caution, and the dose of the 2D6-metabolized medication may need to be reduced.

Contraindications

Terbinafine tablets and cream are not recommended for people who are hypersensitive to terbinafine.

Side Effects

The antagonistic occasions detailed include gastrointestinal side effects (counting the runs, dyspepsia, and stomach torment), liver test anomalies, rashes, urticaria, pruritus, and taste unsettling influences. In common, the antagonistic occasions were mellow, and temporal, and did not lead to suspensionAntagonistic occasions, based on world encounter with terbinafine utilizeincorporatequirky and symptomatic hepatic damage and more once in a while, cases of liver disappointmenta few driving to passing or liver transplant, genuine skin responsesserious neutropenia, thrombocytopenia, angioedema and unfavorably susceptible responses (counting anaphylaxis). Other unfavorable responses that have been detailed incorporate discomfortwearinessheaving, arthralgia, myalgia, and hair misfortune.

Pregnancy & Lactation

Terbinafine tablet: No sufficient and well-controlled studies in pregnant women have been conducted. Terbinafine should not be started during pregnancy since animal reproduction studies are not necessarily predictive of human response, and onychomycosis treatment can be postponed until after the pregnancy has finished. Terbinafine is found in the breast milk of nursing women after oral dosing. Terbinafine is not advised for use in breastfeeding mothers.

Terbinafine cream has been shown to have no negative effects on fetal toxicity and fertility in animals. There is no clinical experience with terbinafine in pregnant women; consequently, terbinafine should not be used unless the possible benefits outweigh the potential risks. Terbinafine is secreted in breast milk, so mothers who are breastfeeding should avoid terbinafine medication.

Precautions & Warnings

Terbinafine pills: The use of terbinafine tablets for the treatment of onychomycosis in patients with and without preexisting liver disease has resulted in rare occurrences of liver failure, some of which have resulted in death or liver transplantation. Patients with substantial underlying systemic illnesses and an unknown causal relationship with terbinafine were seen in the majority of liver cases reported in connection with terbinafine use.

Terbinafine cream should only be used on the outside of the body. Avoid coming into contact with the eyes.

Terbinafine is not indicated for persons with active or chronic liver disease. Pre-existing liver disease should be evaluated before Terbinafine is prescribed. Hepatotoxicity can affect persons with or without a history of liver disease. Before using terbinafine tablets, all patients should have their serum transaminase (ALT and AST) levels tested.

Therapeutic Class

Topical antifungal medicines, drugs for subcutaneous and mycoses

Storage Conditions

Protect from light and store in a cool, dry area below 30°C.

Generic

Terbinafine Hydrochloride

Pharmaceutical Name

ACI Limited